Aim: Number of type 2 diabetes mellitus (T2DM) patients using incretin based therapeutics has significantly increased in past few years. The development of novel incretin based therapeutics from natural sources has become an interesting area of drug discovery. The current review emphasizes the plants having DPP-IV inhibitory activity that can be used in the development of novel anti-diabetic agents.
Methods: The relevant literature was collected form data sources as PubMed, Web of Science and Google Scholar. The references of articles were also examined to obtain further information.
Results: To date, number of plants were documented for its antidiabetic potential through DPP-IV inhibitory activity either in vivo or in vitro. The compounds which exert potent DPP-IV inhibitory action have been identified and their structures have been deduced in some research findings. The DPP-IV inhibitory activity has been compared with positive controls in most of the studies.
Conclusion: The present review reports on natural DPP-IV inhibitors through the assessment of plant profile used in the management of DM and highlights a new pathway for the researches to develop novel molecules from herbal sources with DPP-IV inhibitory activity.
Key words: Diabetes mellitus, incretin, incretin based therapies, dipeptidyl peptidase-IV, plant profile
|
